Inactive Instrument

Press Releases IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

Press Releases

Unlock all the news: Be the first to know and act before the market!

European Study Provides More Evidence Supporting IceCure's ProSense is Safe and Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer	Jul. 10	AQ
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer	Jul. 09	PR
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes	Jul. 01	PR
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024	Jun. 18	PR
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference, Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function	Jun. 13	AQ
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function	Jun. 12	PR
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan	Jun. 04	PR
IceCure Medical : Company Presentation	Jun. 03	PU
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024	May. 29	AQ
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	May. 21	PR
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	May. 20	PR
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	May. 07	PR
IceCure Medical : Company Presentation	Apr. 23	PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	Apr. 16	AQ
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	Apr. 03	AQ
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	Apr. 02	PR
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	Mar. 27	PR
IceCure Medical Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 20	AQ
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	Mar. 19	PR
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes	Mar. 12	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

Press Releases

Filters